Myriad Decision Made

Aug 01, 2011

A federal appeals court has ruled that genes can be patented, and upheld Myriad Genetics' patents for the BRCA1 and BRCA2 genes, reports The New York Times' Andrew Pollack. Myriad uses the genes as the basis for its BRCAnalysis diagnostic test to detect mutations in the BRCA genes. In March 2010, New York Southern District Court Judge Robert Sweet invalidated the patents and said that genes can't be patented because they are products of nature.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Breaking News

The Scan

Teasing Out How Infections Spread

The Chan Zuckerberg Biohub is working with California's health department to sequence viral samples from COVID-19 patients to trace viral introductions, according to the San Francisco Chronicle.

How Far the Butterfly Flies

Despite differences in their migration habits, eastern and western monarch butterflies are genetically similar, according to a study in Molecular Ecology.

Fast COVID-19 Testing for UK

The UK is implementing COVID-19 testing with a 90-minute turnaround time.

PLOS Papers on Mycetoma Molecular Epidemiology, Campylobacter in Retail Meat, More

In PLOS this week: identification of fungal species in subcutaneous infections, sequencing of Campylobacter found in raw meat from retail stores, and more.

Menu